Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a phase I trial.
Tithi BiswasAfshin DowlatiCharles A KunosJohn J PinkNancy L OleinickShakun MalikPingfu FuShufen CaoDebora S BrunoDavid L BajorMonaliben PatelStanton L GersonMitchell MachtayPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Pemetrexed-TRC102 combined with cisplatin/radiotherapy in NS-NSCLC is safe and well tolerated. The recommended phase II dose is chosen to be 200 mg TRC102 along with cisplatin-pemetrexed. No additional safety signal was seen beyond the expected CRT risks. A Phase II trial, integrating post-CRT immunotherapy with this aggressive DNA-damaging regimen is warranted.
Keyphrases
- phase ii
- small cell lung cancer
- open label
- advanced non small cell lung cancer
- clinical trial
- phase iii
- placebo controlled
- cardiac resynchronization therapy
- brain metastases
- double blind
- study protocol
- early stage
- radiation induced
- epidermal growth factor receptor
- circulating tumor
- high grade
- left ventricular
- radiation therapy
- cell free
- locally advanced
- low grade
- single molecule
- squamous cell carcinoma
- heart failure
- human health
- dengue virus
- tyrosine kinase
- atrial fibrillation
- nucleic acid